RESUMO
The effects of indoramin (n = 29) and metoprolol (n = 15) on lipid profiles in hypertensive patients were compared in a double-blind study. Blood samples were taken at baseline, weeks 3 and 4 of placebo administration, and after 4 and 8 weeks of active treatment. The following assays were performed: total cholesterol, total triglycerides, high density lipoprotein (HDL) cholesterol, HDL3 cholesterol, and apoproteins A, AI, and B. The following values were calculated: HDL2 cholesterol, low density lipoprotein (LDL) cholesterol, total cholesterol/HDL cholesterol ratio (Castelli risk ratio I), and LDL cholesterol/HDL cholesterol (Castelli risk ratio II). The results of an overall analysis showed the following significant changes (mean +/- SD) for indoramin: LDL cholesterol, from 129.50 +/- 38.29 to 114.00 +/- 32.41 mg/dl (p less than or equal to 0.001); apoprotein A, from 169.51 +/- 39.83 to 232.48 +/- 34.08 mg/dl (p less than or equal to 0.001); apoprotein AI, from 105.62 +/- 20.70 to 134.68 +/- 21.58 mg/dl; apoprotein B, from 110.13 +/- 34.88 to 122.34 +/- 32.13 mg/dl (p less than or equal to 0.05); and Castelli risk ratio II, from 2.38 to 1.96 (p less than or equal to 0.01). The following significant variations occurred for metoprolol: total cholesterol, from 201.54 +/- 49.21 to 191.80 +/- 51.88 mg/dl (p less than or equal to 0.05); apoprotein A, from 186.78 +/- 62.63 to 227.68 +/- 44.78 mg/dl (p less than or equal to 0.001); apoprotein AI, from 109.12 +/- 34.72 to 131.95 +/- 21.79 mg/dl (p less than or equal to 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
